# Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

> **NCT06175065** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ReAlta Life Sciences, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Acute Exacerbation of Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** RLS-0071
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06175065
- **Lead sponsor:** ReAlta Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-25
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175065, "Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06175065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*